Difference between revisions of "Non-small cell lung cancer, RET-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
Line 14: | Line 14: | ||
|} | |} | ||
===Regimen {{#subobject:91yg11|Variant=1}}=== | ===Regimen {{#subobject:91yg11|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Years of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | | | + | |[https://doi.org/10.1016/s1470-2045(21)00247-3 Gainor et al. 2021 (ARROW<sub>RET</sub>)] |
+ | |2017-2020 | ||
| style="background-color:#91cf61" |Phase I/II (RT) | | style="background-color:#91cf61" |Phase I/II (RT) | ||
|- | |- | ||
|} | |} | ||
− | ''Note: this trial is denoted as ARROW<sub>RET</sub> to distinguish from other trials of the same name. | + | ''Note: this trial is denoted as ARROW<sub>RET</sub> to distinguish from other trials of the same name. This is the phase II dosing.'' |
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
*RET fusion positive | *RET fusion positive | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[Pralsetinib (Gavreto)]] | + | *[[Pralsetinib (Gavreto)]] 400 mg PO once per day |
+ | |||
+ | '''Continued indefinitely''' | ||
===References=== | ===References=== | ||
− | #'''ARROW:''' NCT03037385 | + | #'''ARROW:''' Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 Jul;22(7):959-969. Epub 2021 Jun 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. [https://doi.org/10.1016/s1470-2045(21)00247-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34118197/ PubMed] NCT03037385 |
==Selpercatinib monotherapy {{#subobject:ea894c|Regimen=1}}== | ==Selpercatinib monotherapy {{#subobject:ea894c|Regimen=1}}== |
Revision as of 20:45, 27 November 2021
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
7 regimens on this page
7 variants on this page
|
Advanced or metastatic disease
Pralsetinib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Gainor et al. 2021 (ARROWRET) | 2017-2020 | Phase I/II (RT) |
Note: this trial is denoted as ARROWRET to distinguish from other trials of the same name. This is the phase II dosing.
Biomarker eligibility criteria
- RET fusion positive
Targeted therapy
- Pralsetinib (Gavreto) 400 mg PO once per day
Continued indefinitely
References
- ARROW: Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021 Jul;22(7):959-969. Epub 2021 Jun 9. Erratum in: Lancet Oncol. 2021 Aug;22(8):e347. link to original article PubMed NCT03037385
Selpercatinib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence |
---|---|
Drilon et al. 2020 (LIBRETTO-001) | Phase I/II (RT) |
Biomarker eligibility criteria
- RET fusion positive
Targeted therapy
- Selpercatinib (Retevmo) with or without food, as follows:
- Less than 50 kg: 120 mg PO twice per day
- 50 kg or more: 160 mg PO twice per day
Continued indefinitely
References
- LIBRETTO-001: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. link to original article PubMed NCT03157128